{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:50:46Z","timestamp":1789026646323,"version":"build-2803163510"},"reference-count":20,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Stenotrophomonas maltophilia<\/jats:italic>\n                      is a multidrug-resistant organism with limited antibiotic treatment options. Minocycline and doxycycline may be appropriate, but clinical data are limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      To compare tetracyclines (minocycline and doxycycline [TCN]) with standard of care, sulfamethoxazole-trimethoprim (TMP-SMZ), in\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      pneumonia treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective, 2-center study evaluated patients treated for\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      pneumonia with TCN or TMP-SMZ for clinical success, defined as resolution of leukocytosis, fever, and tachypnea. Patients were classified as treatment with TCN or TMP-SMZ based on definitive agent used for \u226550% of the treatment course and \u22654 days. Inclusion criteria were age \u226518 years,\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      confirmed on respiratory culture from January 2013 to November 2020, and appropriate definitive antibiotic dosing. Pregnancy, incarceration,\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      \u2013resistant or intermediate to definitive therapy, and combination therapy for treatment of\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      pneumonia were exclusion criteria. Secondary outcomes were microbiologic success and recurrence or reinfection within 30 days requiring treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 80 patients were included (21 TCN [15 minocycline, 6 doxycycline], 59 TMP-SMZ). There was no difference in clinical success (28.6% vs 25.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.994), microbiologic success (n = 28, 55.6% vs 66.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.677), or recurrence or reinfection (n = 24, 66.7% vs 26.7%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.092) between TCN and TMP-SMZ, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>\n                      Clinical and microbiologic success rates were similar in patients treated with TCN compared with TMP-SMZ for\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      pneumonia. These data suggest minocycline and doxycycline may be options to treat\n                      <jats:italic toggle=\"yes\">S. maltophilia<\/jats:italic>\n                      pneumonia, but conclusive clinical data continue to be lacking.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231166413","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T07:57:00Z","timestamp":1682495820000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of\n                    <i>Stenotrophomonas maltophilia<\/i>\n                    Pneumonia"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1669-3166","authenticated-orcid":false,"given":"Taha","family":"Alhayani","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Good Samaritan Hospital, TriHealth, Cincinnati, OH, USA"},{"name":"Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn D.","family":"Philpott","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyun","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Gentene","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric W.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Cincinnati Medical Center, UC Health, Cincinnati, OH, USA"},{"name":"James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00019-11"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/340707"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00232"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-015-0061-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.67073"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn301"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01324-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01682-13"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1013"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.03.019"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv456"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw327"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1p217"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106367"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2018.1531145"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311308020004"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1304.061378"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh128"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1581-1584.2001"},{"key":"e_1_3_2_21_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: 30th Informational Supplement","author":"Clinical Laboratory Standards Institute (CLSI)","year":"2020","unstructured":"Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 30th Informational Supplement. CLSI Document M100-S25. CLSI; 2020."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231166413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231166413","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231166413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:08Z","timestamp":1777374788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231166413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/10600280231166413"],"URL":"https:\/\/doi.org\/10.1177\/10600280231166413","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}